Back

Mishaal Gill

Alder Hey Children's Hospital, United Kingdom

Title: Ameloblastic fibroma of the mandible: Report of a case and literature review

Biography

Mishaal Gill has completed her BDS from University of Manchester School of Dentistry, UK in 2013. She has completed Foundation Dental Training in the North West of England then went on to complete core training in Oral and Maxillofacial Surgery in Yorkshire and Merseyside. She has passed all Postgraduate examinations and is a Member of The Royal College of Surgeons Edinburgh. She has published six articles in reputable journals and teaches Restorative Dentistry as a Clinical Restorative Teaching Fellow at Leeds Dental Institute, UK.

Abstract

Ameloblastic fibroma is a rare, slow-growing benign neoplasm, which comprises tissue of odontogenic origin. It constitutes 2% of odontogenic tumors and can occur at any age but tends to have a predilection to present in the first two decades of life. The posterior mandible is the most commonly affected site. Herein, we describe the case of a 6-year-old Caucasian
male who presented to the Oral and Maxillofacial Department at Alder Hey Children's’ Hospital, Liverpool, United Kingdom with a painless expansive mass in the left mandible which was diagnosed as a benign ameloblastic fibroma. The lesion was surgically enucleated and reconstructed with a parietal calvarial bone graft. A literature search using the PubMed, Embase
and CINAHL databases was performed. The terms included in the search were Ameloblastic, Fibroma, Ameloblastic Fibroma and Odontogenic Tumor. We further meshed all search terms to incorporate a wide range of alternative phrases surrounding the topic. Our results produced 604 papers, from which duplicates were removed and this left 334 papers to review. Of these
papers, the highest level of evidence was an abstract on a systematic review by Chrcanovic et al 2017. The management of AF is challenging, and there is no clear consensus regarding a conservative versus a more aggressive approach. In our opinion, a ‘case specific’ approach is appropriate. The aims of treatment are to remove the tumor and decrease the chances of recurrence while preserving adjacent vital structures when safe to do so.